VIYASH SCIENTIFIC LIMITED
VIYASH · General/Diversified · NSE
₹208
Current Market Price
Fair Value (DCF)
₹100
Margin of Safety
-52.0%
Updated 11h ago
YieldIQ Score
55/100
Piotroski F-Score
8/9
Economic Moat
Narrow
Confidence
31%
ROE
—
Debt/Equity
0.55
WACC
11.1%
Market Cap
₹9,080 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
9.1%
Return on capital employed
EV / EBITDA
26.6×
Enterprise multiple
Debt / EBITDA
1.4×
Leverage vs earnings
Interest Coverage
1.8×
EBIT covers interest
Current Ratio
1.73×
Short-term liquidity
Asset Turnover
0.97×
Revenue per ₹ of assets
Revenue CAGR (3Y)
3.1%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹208.05
Bear case
₹58.84
MoS -253.6%
Base case
₹99.76
MoS -108.6%
Bull case
₹124.66
MoS -66.9%
Ratio Trends
VIYASH · last 8 annual periods
ROE
2.8%
ROCE
13.3%
Operating Margin
—
Debt / Equity
0.62×
PE
—
EV / EBITDA
—
Historical Financials
VIYASH · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1362 Cr | ₹1413 Cr | ₹367 Cr | ₹361 Cr | ₹1547 Cr | +3.2% |
| EBITDA | — | ₹118 Cr | ₹-52.2 Cr | ₹53.3 Cr | ₹167 Cr | +9.0% |
| EBIT | ₹161 Cr | ₹69.2 Cr | ₹-77.9 Cr | ₹15.1 Cr | — | -44.7% |
| PAT | ₹104 Cr | ₹45.1 Cr | ₹-92.4 Cr | ₹1.3 Cr | ₹21.9 Cr | -32.3% |
| EPS (diluted) | ₹3.85 | ₹1.65 | ₹-3.77 | ₹-0.04 | — | — |
| CFO | ₹115 Cr | ₹30.6 Cr | ₹16.8 Cr | ₹30.6 Cr | ₹83.4 Cr | -7.7% |
| CapEx | — | — | — | — | ₹-39.1 Cr | — |
| FCF | — | — | — | — | ₹44.3 Cr | +0.0% |
| Total Assets | — | ₹1451 Cr | ₹1529 Cr | ₹1540 Cr | ₹1602 Cr | +2.5% |
| Total Debt | — | — | ₹215 Cr | ₹309 Cr | ₹481 Cr | +22.3% |
| Shareholders' Equity | — | — | ₹699 Cr | ₹657 Cr | ₹770 Cr | +2.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
VIYASH vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| STAR STAR | — | — | Pending | 138.9% | — |
| AKUMS AKUMS | — | — | Pending | 11.0% | — |
| PGHL PROCTER & GAMBLE HEALTH L | -32.5% | 45 | Overvalued | 3.1% | — |
| SHILPAMED SHILPAMED | — | — | Pending | 3.3% | — |
| SUDEEPPHRM SUDEEPPHRM | — | — | Pending | 28.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for VIYASH in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of VIYASH →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for VIYASH →
Compare
Head-to-head with peers
Compare VIYASH side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse VIYASHNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.